Viking Therapeutics and NextCure, both clinical-stage biopharma companies, are being compared on affordability and analyst ratings.
1 report, 1 independent
Updated Aug 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Viking Therapeutics and NextCure, both clinical-stage biopharma companies, are being compared on affordability and analyst ratings.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Viking Therapeutics
company in San Diego, United States
- The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
-
MarketBeat
American personal finance blog
Related events
- MarketBeat provided analyst ratings and targets for small-cap healthcare companies Emergent BioSolutions and Entrada Therapeutics.
- MarketBeat provided consensus price targets and ratings, while DBV Technologies and XTL Biopharmaceuticals compete in the small-cap healthcare market.
- MarketBeat is reporting on analyst recommendations and consensus target prices for small-cap healthcare companies Myriad Genetics and Applied DNA Sciences.
- MarketBeat is providing consensus price targets and analyst recommendations for consumer staples companies, including JBS S.A. and Inspire Veterinary Partners.
- Pro-Dex, Inc. is competing in the medical-surgical products market and was rated and analyzed by MarketBeat on September 1, 2026.